These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 26264576)

  • 1. Elucidating the role of the A2A adenosine receptor in neurodegeneration using neurons derived from Huntington's disease iPSCs.
    Chiu FL; Lin JT; Chuang CY; Chien T; Chen CM; Chen KH; Hsiao HY; Lin YS; Chern Y; Kuo HC
    Hum Mol Genet; 2015 Nov; 24(21):6066-79. PubMed ID: 26264576
    [TBL] [Abstract][Full Text] [Related]  

  • 2. AMPK-α1 functions downstream of oxidative stress to mediate neuronal atrophy in Huntington's disease.
    Ju TC; Chen HM; Chen YC; Chang CP; Chang C; Chern Y
    Biochim Biophys Acta; 2014 Sep; 1842(9):1668-80. PubMed ID: 24946181
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantitative proteomic analysis of induced pluripotent stem cells derived from a human Huntington's disease patient.
    Chae JI; Kim DW; Lee N; Jeon YJ; Jeon I; Kwon J; Kim J; Soh Y; Lee DS; Seo KS; Choi NJ; Park BC; Kang SH; Ryu J; Oh SH; Shin DA; Lee DR; Do JT; Park IH; Daley GQ; Song J
    Biochem J; 2012 Sep; 446(3):359-71. PubMed ID: 22694310
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hyperactivation of D1 and A2A receptors contributes to cognitive dysfunction in Huntington's disease.
    Tyebji S; Saavedra A; Canas PM; Pliassova A; Delgado-García JM; Alberch J; Cunha RA; Gruart A; Pérez-Navarro E
    Neurobiol Dis; 2015 Feb; 74():41-57. PubMed ID: 25449908
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reversal of cellular phenotypes in neural cells derived from Huntington's disease monkey-induced pluripotent stem cells.
    Carter RL; Chen Y; Kunkanjanawan T; Xu Y; Moran SP; Putkhao K; Yang J; Huang AH; Parnpai R; Chan AW
    Stem Cell Reports; 2014 Oct; 3(4):585-93. PubMed ID: 25358787
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression, pharmacology and functional activity of adenosine A1 receptors in genetic models of Huntington's disease.
    Ferrante A; Martire A; Pepponi R; Varani K; Vincenzi F; Ferraro L; Beggiato S; Tebano MT; Popoli P
    Neurobiol Dis; 2014 Nov; 71():193-204. PubMed ID: 25132555
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FOXOs modulate proteasome activity in human-induced pluripotent stem cells of Huntington's disease and their derived neural cells.
    Liu Y; Qiao F; Leiferman PC; Ross A; Schlenker EH; Wang H
    Hum Mol Genet; 2017 Nov; 26(22):4416-4428. PubMed ID: 28973411
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased 5-methylcytosine and decreased 5-hydroxymethylcytosine levels are associated with reduced striatal A2AR levels in Huntington's disease.
    Villar-Menéndez I; Blanch M; Tyebji S; Pereira-Veiga T; Albasanz JL; Martín M; Ferrer I; Pérez-Navarro E; Barrachina M
    Neuromolecular Med; 2013 Jun; 15(2):295-309. PubMed ID: 23385980
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Amelioration of Huntington's disease phenotype in astrocytes derived from iPSC-derived neural progenitor cells of Huntington's disease monkeys.
    Cho IK; Yang B; Forest C; Qian L; Chan AWS
    PLoS One; 2019; 14(3):e0214156. PubMed ID: 30897183
    [TBL] [Abstract][Full Text] [Related]  

  • 10. cAMP-response element-binding protein contributes to suppression of the A2A adenosine receptor promoter by mutant Huntingtin with expanded polyglutamine residues.
    Chiang MC; Lee YC; Huang CL; Chern Y
    J Biol Chem; 2005 Apr; 280(14):14331-40. PubMed ID: 15689617
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pramipexole reduces soluble mutant huntingtin and protects striatal neurons through dopamine D3 receptors in a genetic model of Huntington's disease.
    Luis-Ravelo D; Estévez-Silva H; Barroso-Chinea P; Afonso-Oramas D; Salas-Hernández J; Rodríguez-Núñez J; Acevedo-Arozena A; Marcellino D; González-Hernández T
    Exp Neurol; 2018 Jan; 299(Pt A):137-147. PubMed ID: 29056363
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of soluble tumor necrosis factor is therapeutic in Huntington's disease.
    Hsiao HY; Chiu FL; Chen CM; Wu YR; Chen HM; Chen YC; Kuo HC; Chern Y
    Hum Mol Genet; 2014 Aug; 23(16):4328-44. PubMed ID: 24698979
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PIAS1 modulates striatal transcription, DNA damage repair, and SUMOylation with relevance to Huntington's disease.
    Morozko EL; Smith-Geater C; Monteys AM; Pradhan S; Lim RG; Langfelder P; Kachemov M; Kulkarni JA; Zaifman J; Hill A; Stocksdale JT; Cullis PR; Wu J; Ochaba J; Miramontes R; Chakraborty A; Hazra TK; Lau A; St-Cyr S; Orellana I; Kopan L; Wang KQ; Yeung S; Leavitt BR; Reidling JC; Yang XW; Steffan JS; Davidson BL; Sarkar PS; Thompson LM
    Proc Natl Acad Sci U S A; 2021 Jan; 118(4):. PubMed ID: 33468657
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selective degeneration in YAC mouse models of Huntington disease.
    Van Raamsdonk JM; Warby SC; Hayden MR
    Brain Res Bull; 2007 Apr; 72(2-3):124-31. PubMed ID: 17352936
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adenovirus vector-based in vitro neuronal cell model for Huntington's disease with human disease-like differential aggregation and degeneration.
    Dong X; Zong S; Witting A; Lindenberg KS; Kochanek S; Huang B
    J Gene Med; 2012 Jul; 14(7):468-81. PubMed ID: 22700462
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Manifestation of Huntington's disease pathology in human induced pluripotent stem cell-derived neurons.
    Nekrasov ED; Vigont VA; Klyushnikov SA; Lebedeva OS; Vassina EM; Bogomazova AN; Chestkov IV; Semashko TA; Kiseleva E; Suldina LA; Bobrovsky PA; Zimina OA; Ryazantseva MA; Skopin AY; Illarioshkin SN; Kaznacheyeva EV; Lagarkova MA; Kiselev SL
    Mol Neurodegener; 2016 Apr; 11():27. PubMed ID: 27080129
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Astrocytes generated from patient induced pluripotent stem cells recapitulate features of Huntington's disease patient cells.
    Juopperi TA; Kim WR; Chiang CH; Yu H; Margolis RL; Ross CA; Ming GL; Song H
    Mol Brain; 2012 May; 5():17. PubMed ID: 22613578
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Apoptosis in Huntington's disease.
    Hickey MA; Chesselet MF
    Prog Neuropsychopharmacol Biol Psychiatry; 2003 Apr; 27(2):255-65. PubMed ID: 12657365
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The A2A adenosine receptor rescues the urea cycle deficiency of Huntington's disease by enhancing the activity of the ubiquitin-proteasome system.
    Chiang MC; Chen HM; Lai HL; Chen HW; Chou SY; Chen CM; Tsai FJ; Chern Y
    Hum Mol Genet; 2009 Aug; 18(16):2929-42. PubMed ID: 19443488
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Progerin-Induced Transcriptional Changes in Huntington's Disease Human Pluripotent Stem Cell-Derived Neurons.
    Cohen-Carmon D; Sorek M; Lerner V; Divya MS; Nissim-Rafinia M; Yarom Y; Meshorer E
    Mol Neurobiol; 2020 Mar; 57(3):1768-1777. PubMed ID: 31834602
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.